Vertex Pharmaceuticals Incorporated

NASDAQ (VRTX) US$ 471,12 01/11 16:00 -4,86 -1,02%

24hGold TrendPower©: -50

Cours préc.

Ouverture

475,98

471,06

Bas

Haut

463,15

475,49

Volume

Var. YTD

1 230 238

15,79%

Shares Oustanding

Mkt Cap Oustanding

249 070 000

117 341 858 400

Année b/h

52 sem. b/h

391,02 - 510,64

463,15 - 475,49

var. 1 mois

var. 52 sem.

0,29%

27,56%

Vertex Pharma est une société basée aux Etats-Unis D'Amerique.

Vertex Pharma est cotée aux Etats-Unis D'Amerique. Sa capitalisation boursière aujourd'hui est 117,3 milliards US$ (107,8 milliards €).

La valeur de son action a atteint son plus bas niveau récent le 12 mars 2004 à 10,00 US$, et son plus haut niveau récent le 01 novembre 2024 à 471,12 US$.

Vertex Pharma possède 249 070 000 actions en circulation.

Communiqués de Presse

22/08/2017	See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
14/08/2017	Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn’t Worth the Risk
10/08/2017	IHS Markit Score downgrades Vertex Pharmaceuticals Inc to 64 out of 100, ranking positively in only one out of three available IHS Markit categories.
09/08/2017	Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher
03/08/2017	Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons
03/08/2017	Corporate News Blog - Vertex Pharma Announces Approval from the FDA For KALYDECO in More Than 600 Patients Suffering from Cystic Fibrosis
02/08/2017	Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote
27/01/2016	Will Vertex Pharmaceuticals’ Valuation Multiple Improve?
26/01/2016	Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
26/01/2016	5:23 pm Vertex Pharma: Health Canada approves PrORKAMBI
26/01/2016	Orkambi: Recent Addition to the Vertex Portfolio
26/01/2016	Vertex draws upside bet before earnings
25/01/2016	Will Higher Expenses Hurt Vertex's (VRTX) 4Q Earnings?
25/01/2016	What Are Wall Street’s Estimates for Vertex Pharmaceuticals?
25/01/2016	Vertex Pharmaceuticals: What Are Analysts’ Estimates?
20/01/2016	Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs
18/01/2016	Nivalis' N91115 Gets Orphan Drug Status for Cystic Fibrosis
15/01/2016	4 Biotech Stocks Looking Good this Earnings Season
15/01/2016	Vertex Pharmaceuticals (VRTX) Jumps: Stock Moves Up 5.8%
05/01/2016	Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2015 Financial Results